evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,678 questions · 4,859 findings · 283 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,225 · 25.2%GRADE not reported 215 · 4.4%Very low 1,241 · 25.5%Low 1,210 · 24.9%Moderate 776 · 16%High 192 · 4%

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

FEV1 % predicted: relative change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

FEV1 % predicted: absolute change from baseline · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype
1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Adverse events ‐ treatment emergent · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor showed no clear difference in adverse events: number of participants with treatment‐emergent… compared with control (ivacaftor alone or tezacaftor plus ivacaftor) (moderate certainty).

1 finding from 1 review

Summary of findings ‐ triple therapy: elexacaftor‐tezacaftor‐ivacaftor vs control (ivacaftor alone or tezacaftor plus ivacaftor)

Time to first pulmonary exacerbation · adults and children aged 12 years and over with cystic fibrosis and either F508del/gating variant or F508del/residual function genotype

The review found no eligible studies for this question.

1 finding from 1 review

Minoxidil vs placebo

Short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of · adults with alopecia areata

It is very uncertain whether summary of findings table ‐ Topical hair growth stimulants (minoxidil) changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroids vs single course

B3: Caesarean section – an all women · the woman

Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroids showed no clear difference in B3: Caesarean section – an all women compared with single course (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroids vs single course

C1: Total deaths (after randomisation) up to early childhood · the child

Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroids showed no clear difference in C1: Total deaths (after randomisation) up to early childhood compared with single course (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroids vs single course

C2: Neurodevelopmental impairment at early childhood · the child

Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroids showed no clear difference in C2: Neurodevelopmental impairment at early childhood compared with single course (high certainty).

1 finding from 1 review

Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroids vs single course

C3: Survival free of neurodevelopmental impairment at early childhood · the child

Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroids showed no clear difference in C3: Survival free of neurodevelopmental impairment at early childhood compared with single course (high certainty).

1 finding from 1 review

Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroids vs single course

C4: Survival free of major neurodevelopmental impairment atearly childhood · the child

Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroids showed no clear difference in C4: Survival free of major neurodevelopmental impairment atearly… compared with single course (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroids vs single course

D1: Total deaths (after randomisation) up to mid‐ to later childhood · the child

Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroids showed no clear difference in D1: Total deaths (after randomisation) up to mid‐ to later childhood compared with single course (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroids vs single course

D2: Neurocognitive impairment atmid‐ to later childhood · the child

Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroids showed no clear difference in D2: Neurocognitive impairment atmid‐ to later childhood compared with single course (low certainty).

1 finding from 1 review

Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroids vs single course

D3: Survival free of neurocognitive impairment atmid‐ to later childhood · the child

Summary of findings table ‐ Repeat dose(s) of prenatal corticosteroids showed no clear difference in D3: Survival free of neurocognitive impairment atmid‐ to later… compared with single course (moderate certainty).

1 finding from 1 review